Technology Innovation Institute’s Cryptography Research Centre in Abu Dhabi Collaborates with Yale University
Abu Dhabi and the UAE are working to pioneer breakthroughs in post-quantum cryptography and neuromorphic computing through an international partnership between Technology Innovation Institute’s (TII) Cryptography Research Centre (CRC) and Yale University, an Ivy League research university in Connecticut, United States.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210106005376/en/
Dr. Najwa Aaraj, Chief Researcher at Cryptography Research Centre (Photo: AETOSWire)
The two institutions will first join forces on ‘Post-Quantum Lightweight Crypto Hardware Accelerators and Trusted Execution Environment Designs’, a project at the intersection of emerging technologies that focuses on developing quantum-resistant crypto schemes within the context of emerging quantum algorithms that can be run on a sufficiently large quantum computer. By leveraging post-quantum cryptographic (PQC) algorithms, the project aims to guarantee the necessary measures of security even as today’s public cryptographic standards, such as RSA and Elliptic Curve Cryptography (ECC), become ineffective when a powerful quantum computer is built and can run Shor’s quantum algorithm. The project is also exploring post-quantum lightweight cryptography with a focus on highly constrained devices.
The neuromorphic computing project, ‘Energy-based Probing for Robust and Explainable Spiking Neural Networks’, takes inspiration from the brain to create energy-efficient hardware for information processing and is capable of highly sophisticated tasks. The project examines Spiking Neural Networks (SNNs), which have become popular as an energy-efficient alternative for implementing standard artificial intelligence tasks. Spikes or binary events drive communication and computation in SNNs that are close to biological neuronal processing and offer the benefit of event-driven hardware operations.
The central focus of the collaboration is to explore the design space of the energy-accuracy-robustness-explainability trade-off and to design the hardware/software necessary to create truly functional intelligent systems. To ensure there is no overlap, both entities have been tasked with managing specific areas of the research in both projects.
Speaking on the partnership, Dr Najwa Aaraj, Chief Researcher at Cryptography Research Centre, said: “We are excited to work with peers from Yale University in carrying out groundbreaking research in these two vital fields. At the Cryptography Research Centre, we are creating a knowledge-driven ecosystem powered by like-minded scientists and researchers – all focused on designing breakthrough solutions in different areas of cryptography.”
Jakub Szefer, Associate Professor of Electrical Engineering and Computer Science, and Priya Panda, Assistant Professor of Electrical Engineering, from Yale University, said: “By working collaboratively with Cryptography Research Centre, we have an opportunity to apply shared expertise across post-quantum cryptography and neuromorphic computing research. We are optimistic that this partnership will yield effective research outcomes for greater impact.”
Technology Innovation Institute, the ‘applied research’ pillar of Advanced Technology Research Council (ATRC), is a pioneering global research and development centre that focuses on applied research and new-age technology capabilities. The institute has seven initial dedicated research centres in quantum, autonomous robotics, cryptography, advanced materials, digital security, directed energy and secure systems. By working with exceptional talent, universities, research institutions and industry partners from all over the world, the Institute connects an intellectual community and contributes to building an R&D ecosystem in Abu Dhabi and the UAE. The Institute reinforces Abu Dhabi and the UAE’s status as a global hub for innovation and contributes to the broader development of the knowledge- based economy.
For more information about Cryptography Research Centre (CRC) please visit
tii.ae/cryptographytii.ae/cryptography
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210106005376/en/
Contact information
Technology Innovation Institute
Aisha Shaikh, +971555423718
aisha.shaikh@tii.ae
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
